Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBL-024 + docetaxel
- Development stage
- Unknown
- Lead developer
- LEADS BioLabs
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**LBL-024 + docetaxel** is an investigational intravenous anticancer co-administration regimen being evaluated by Leads Biolabs in advanced non-small cell lung cancer. LBL-024 is a tetravalent PD-L1 × 4-1BB bispecific antibody designed to block PD-L1-mediated immune-checkpoint signaling while conditionally agonizing 4-1BB in the tumor microenvironment to enhance T-cell activation. Docetaxel is a taxane chemotherapy that binds tubulin, stabilizes microtubules, and inhibits mitosis. The regimen is being studied in a recruiting Phase 2 substudy of an advanced solid-tumor trial, including an LBL-024 plus docetaxel cohort for advanced non-small cell lung cancer.
- Other names
- docetaxel + LBL-024LBL 024 + docetaxelLBL024 + docetaxel
02
Targets
TNFRSF9 (CD137 extracellular domain)CD274 (Programmed cell death protein 1 ligand 1)Microtubule
Beyond the preview
Go deeper on LBL-024 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBL-024 + docetaxel.